Rigel Pharmaceuticals Inc is a clinical-stage drug development company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.
Our STA Research today shows that the stock is due for a 96% increase in it’s stock valuation within a 6 to 12 month duration.  Yahoo Finance Analyst Report indicates a 96% increase. Our STA Research rating indicates the stock as a Very Strong Buy with Bearish near term sentiment.
